reason report
await close amneal transact
bottom line manag commentari indic everyth
progress well toward close amneal transact
remain optimist new amneal pipelin
portfolio also note believ exceed previous
announc synergi target updat model
reflect faster eros base busi gener product
partial off-set increas albenza sale
push launch gener competitor earli
lower ep ep
continu believ new amneal
portfolio best posit drive growth difficult us gener
environ maintain outperform rate pt stock
look forward detail amneal pipelin guidanc
follow close transact
ftc process amneal deal progress smoothli
deal close track manag note close
final group product ftc ask divest
also found potenti partner will take product
manag estim number product divest
less dozen appear chang
commentari provid earli januari point manag
see major issu would impact process
could potenti upsid synergi
previous announc amneal deal manag
reiter guidanc run-rat synergi within three
year post amneal close manag comment would
disappoint synergi could achiev note
includ revenu synergi partial includ
synergi move product contract manufactur organ
amneal in-hous manufactur site
manag believ late inning headwind
face gener manag point exampl compani
industri start prune portfolio longer suppli
product unprofit believ late inning
disrupt occur custom consolid
lot room left downward pressur
separ manag note impact harmon
mp group purchas consortium combin alreadi underway
expect nomin impact busi
ev/ebitda multipl
net debt total capit
gener
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
mix result gener busi product
epinephrin auto-injector hold strong older
gx budesonid adderal xr sale quarter neg
impact entri one addit player near end
adderal xr also erod increas competit gx opana er
continu push forward doctor remind program
start see prescript volum stabil recent manag
remain hope see potenti upward trend product
manufactur market epinephrin auto-injector
roughli market share today essenti peak
capac manag note product price mylan
mp author gener ag even anoth ab-rat
gener enter market would like priorit captur
share oppos therefor manag believ
product pretti good sustain potenti
later year gx welchol launch inventori readi
expect launch first wave approv gx aggrenox
work challeng scale
manufactur product product overlap
amneal current compani market
product remain seen manag proceed
manag remain commit central nervou system
franchis rytari strong far manag
seen carri forward manag cautious optimist
momentum continu full year also
grant new formul patent expir could maintain
durabl asset manag note trial on-going
ip rytari litig push may open potenti
settlement talk manag also plan initi phase trial
next gen rytari post amneal deal close
manag open-mind strateg footprint
new amneal manag note follow amneal transact
close plan re-evalu strateg footprint beyond current
portfolio open consid build brand portfolio
and/or anoth franchis also evalu adjac
relat cash pay distribut busi
new amneal take wait see approach
particip biosimilar manag highlight biosimilar
still need overcom challeng intellectu properti approv
adopt perspect time plan
market biosimilar rather manufactur new compani
two biosimilar pipelin amneal current partnership
adello submit applic biosimilar last year
plan submit applic biosimilar neulasta year
combin amneal chang top-lin growth profil
oper margin improv low-mid-teen
driven stand-alon cost save addit higher margin amneal busi
impax brand/gener hybrid biz cost synergi amneal combin see
strong profit cash flow drive improv leverag
provid manag flexibl explor addit busi develop
close amneal transact
initi phase studi
patent litig decis
fda approv copaxon
file bla amneal
figur chang model
lp estim note number except ep margin
note revenu
changevalu changevarianceconsensusactu vs constherapeut specialti gener basic dilut non-gaap adjustmentstot one-tim net inc
use weight averag ev/ebitda multipl deriv pt
ebitda visibl drive ipxl higher vs impli multipl
delay close amneal transact limit visibl composit amneal
portfolio delay amneal pipelin product develop cost save delay lower
expect earlier expect gener competit rytari
number except per share data
slight declin time
net debt ebitda ratio
number except per share data
number except per share data
budesonid pulmicort respul -- teva
propranolol hcl inder -- teva
estrac approv expect launch
number except per share data
prior launch product
total prior launch product
number except per share data
aggrenox approv launch
nasonex approv launch
zetia approv launch
minastrin fe approv launch
concerta approv expect launch
copaxon gener alreadi market pend approv
gleevec gener alreadi market pend approv
viagra launch teva day exclus tent approv
seroquel xr gener alreadi market pend approv
lialda launch jan zydu day exclus expir
copaxon gener alreadi market pend approv
canasa assum ftf day exclus pend approv
exelon patch gener alreadi market pend approv
faslodex litig progress assum settlement ftf sandoz pend approv
norvir assum patent expir jan pend approv
saphri filer lost patent pend approv
truvada assum emtricitabin patent key pend approv
amitiza assum settlement month ftf pend approv
sensipar case progress pend approv
vimpat lost patent expir pend approv
toviaz filer lost patent expir tent approv
velcad filer lost patent expir pend approv
alimta filer lost patent pend approv
vyvans lost feb patent tent approv
xyrem assum launch day hikma pend approv
onglyza franchis lost jul patent pend approv
number except per share data
sale
note exclud amneal sale includ amneal sale combin compani sale begin
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
accru profit share royalti
current portion ltd
number except per share data
adjust reconcil ni net cash oper
tax expens stock option rsa
accru profit share royalti expens net payment
reserv ture receiv
sale asset
loss extinguish debt
net chang fair valu deriv
recognit defer revenu
chang fair valu conting consider
decreas increas work capit
payment busi acquisit
purchas properti plant equip capital-expenditure
payment licens agreement
invest cash surrend valu insur
proce repay tolmar loan
proce sale intang asset
maturities/purchas short-term invest
net invest
payment defer financ fee
purchas bond hedg deriv asset
proce sale warrant
tax benefit stock option rsa
proce exercis stock option espp
net financ
effect exchang rate chang cash/ cash equival
net chang equival
